For years, people looking for systemic hair growth treatments without taking daily hormone-blocking pills like finasteride turned to low-dose oral minoxidil tablets off-label. However, traditional immediate-release tablets were created for high blood pressure. When swallowed, standard pills cause a rapid spike of minoxidil in the bloodstream. This sudden flood often triggers unwanted cardiovascular side effects, including a racing heart, low blood pressure, and swollen ankles.
VDPHL01 solves this safety problem through a specialized hydrogel matrix. Instead of dissolving all at once, the tablet slowly releases minoxidil over many hours as it passes through the digestive tract. This keeps drug levels steady in the blood—high enough to keep scalp hair roots in active growth, but low enough to avoid triggering heart palpitations or blood pressure drops.
What Is It and How Does It Work?
The tablet operates through Extended Hydrogel Release, Steady Blood Bioavailability, and Potassium Channel Hair Activation.
-
The Problem with Standard Pills: Swallowing standard immediate-release minoxidil causes a quick surge of the drug in the bloodstream. This sudden peak dilates blood vessels across the body, forcing the heart to pump faster to compensate.
-
The Extended-Release Gel Matrix: VDPHL01 uses a specialized gel-based tablet core. As the tablet moves through the stomach and intestines, it absorbs fluid and turns into a soft gel that slowly releases minoxidil at a controlled rate.
-
Maintaining the Growth Zone: By releasing the drug steadily, the tablet maintains minoxidil levels above the minimum concentration needed for hair growth without causing high blood spikes.
-
Opening Root Potassium Channels: Once the medicine reaches the scalp, it opens potassium channels in hair roots. This signal relaxes local micro-blood vessels, increases nutrient flow, and commands miniaturized hair roots to stay in the active growth phase longer.
The Science: Clear Results from Pivotal Phase 3 Trials
The Phase 3 registration program (including Study 304 and Study 302) evaluated the tablet across more than 1,000 adult male participants over six months of daily use:
-
Significant Hair Density Gains: In the Phase 3 Study 304 trial involving 536 men, participants taking the once-daily pill gained an average of 28.6 non-vellus hairs per square centimeter over six months, significantly outperforming placebo.
-
High Subject-Reported Improvement: Over 55 to 79 percent of participants reported visible improvements in scalp coverage, with measurable density gains appearing as early as Month 2.
-
Zero Heart-Related Safety Events: Across late-stage testing, the extended-release formulation produced zero treatment-related cardiac adverse events or dangerous blood pressure drops.
-
Non-Hormonal Efficacy: Because minoxidil stimulates hair growth through cell signaling rather than blocking hormones, blood tests confirmed zero disruption of systemic testosterone or DHT.
“With topline findings from our Phase 3 Study 304, we have now reported positive topline placebo-controlled data from two registration-directed trials… If approved, VDPHL01 could give physicians greater confidence to offer treatment and help more patients see a meaningful improvement in their pattern hair loss.”— Veradermics Clinical Development Team.
When Will It Be Available?
-
Current Stage: Phase 3 registration trials in men are complete with positive primary endpoints met; Phase 2/3 trials in women (Study 306) are actively underway.
-
Timeline: Final 12-month extension data and female trial results will report across 2027. Formal New Drug Application (NDA) submissions to the US FDA and international regulators are targeted for late 2027 to 2028, pointing toward potential commercial prescription availability between 2028 and 2029.
How You Can Benefit from This Science Now
-
Protect Hair Density Early: Advanced pills like VDPHL01 require living, viable hair roots to work. Maintaining your current density with existing proven methods prevents shrinking roots from permanently scarring over.
-
Discuss Off-Label Low-Dose Options: If you want systemic minoxidil benefits today without waiting for extended-release approval, consult a dermatologist about whether standard low-dose oral minoxidil (0.625 mg to 2.5 mg daily) is safe for your cardiovascular profile.
-
Enhance Scalp Circulation: Hair roots need strong blood flow to stay active. A daily four-minute circular fingertip scalp massage helps relieve tissue tightness and supports blood vessel flexibility.
-
Use Micro-Stamping to Boost Topical Penetration: If you prefer topical minoxidil over pills, using a gentle 0.5 mm shallow micro-stamper once weekly creates temporary skin channels that help liquid serums reach the root bulb.
-
Do Not Crushing Commercial Tablets: Do not try to make your own extended-release setup by crushing or splitting standard immediate-release minoxidil pills. Altering regular tablets ruins their coating and can cause a rapid, dangerous surge of the drug into your bloodstream.
Action: Give your scalp a firm, four-minute circular fingertip massage tonight to encourage healthy blood circulation and support nutrient delivery to your hair roots.